Your cart is empty.
Männedorf, Switzerland, April 14, 2011 – Dr Francisco Quintana from the Center for Neurologic Diseases at the Brigham and Women's Hospital, Harvard Medical School, Massachusetts, is using Tecan microarray solutions as part of a systems biology approach to studying the immune response in multiple sclerosis. The laboratory has developed antigen and reverse phase protein microarrays for a wide range of studies, as Dr Quintana explained: “We construct microarrays using proteins, peptides or lipids of interest, and hybridize these with samples from either MS patients or animal models of disease using a HS 4800™ Pro hybridization station. The arrays are read with a PowerScanner™ and analyzed with the help of Tecan’s software to identify potential biomarkers for MS, elucidate mechanisms of pathogenesis and ascertain which signaling pathways are activated in response to therapeutic interventions.”
“Automation was a major consideration when assessing microarray instruments as, although we were already performing a majority of these studies manually, automation reduces the ‘noise’ inherent in manually processed experiments. This helps to improve the quality of results and simplify data interpretation. Coupling the HS Pro with the walkaway operation provided by the PowerScanner gives us the capacity we need, without causing an excessive drain on resources,”
To find out more on Tecan’s microarray solutions, visit http://www.tecan.com/microarray
Tecan Trading AG
Tel +41 (0)44 922 81 11
Fax +41 (0)44 922 81 12
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of instruments and automated workflow solutions for laboratories in the life sciences sector. As an original equipment manufacturer, Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2009, Tecan generated sales of CHF 392 million (USD 361.2 million; EUR 259.6 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN CH0012100191).